IN BRIEF: Evgen Pharma's SFX-01 effective on tumour cells
IN BRIEF: Evgen Pharma's SFX-01 effective on tumour cells
Read moreFri, 08th Oct 2010 17:29
IN BRIEF: Evgen Pharma's SFX-01 effective on tumour cells
Read moreIN BRIEF: Evgen SFX-01 granted orphan drug designation by US FDA
Read more(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced preclinical data demonstrating that 'SFX-01' was effective in in-vitro models of certain blood cancers on Tuesday.
Read moreIN BRIEF: Evgen Pharma files brain tumour treatment request with FDA
Read moreIN BRIEF: Evgen Pharma encouraged by early data for SFX-01
Read moreAIM WINNERS & LOSERS: Star Phoenix wins new deal; Ebiquity revenue up
Read moreEvgen Pharma halts trial as SFX-01 drug fails to help Covid patients
Read moreAIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle
Read more(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced the results of the interim safety and futility assessment readout of the first 100 patients treated in the 'STAR' Covid-19 trial of its lead asset, 'SFX-01', on Friday.
Read moreUK shareholder meetings calendar - next 7 days
Read moreTRADING UPDATES: GB Group rebuilds dividend; IPF ups 2021 profit view
Read moreTRADING UPDATES: Synectics loss narrows; Active Energy loss widens
Read more(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced new preclinical data on Monday, which showed 'SFX-01' could be of benefit to metastatic breast cancer (mBC) patients who had become resistant to CDK4/6 inhibitors.
Read moreIN BRIEF: Evgen Pharma appoints Huw Jones as chief medical officer
Read moreIN BRIEF: Evgen Pharma notes publication on sulforaphane in Covid-19
Read more